PepGen (PEPG) Profit After Tax (2021 - 2026)
PepGen (PEPG) posted Profit After Tax of -$17.8 million for Q1 2026, up 2.57% sequentially from -$18.3 million in Q4 2025, and up 40.95% YoY from -$12.7 million in Q1 2025.
PepGen (PEPG) Profit After Tax (2021 - 2026) Analysis & Trends
PepGen has reported Profit After Tax for 6 years, with the latest figure at -$17.8 million in Q1 2026.
- Quarterly Profit After Tax rose 40.95% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.2 million (up 24.39% YoY) and the FY2025 annual result came in at -$89.7 million, changed 0.36% from the prior year.
- Profit After Tax rose to -$17.8 million in Q1 2026 per PEPG's latest filing, from -$18.3 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$14.9 million in Q4 2022 and troughed at -$30.2 million in Q1 2025.
- A 5-year average of -$20.3 million and a median of -$18.6 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2026: Profit After Tax slumped 221.3% in 2022, then jumped 40.95% in 2026.
- Over 5 years, Profit After Tax stood at -$14.9 million in 2022, then retreated by 29.91% to -$19.4 million in 2023, then fell by 14.68% to -$22.3 million in 2024, then grew by 17.75% to -$18.3 million in 2025, then gained by 2.57% to -$17.8 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$17.8 million, -$18.3 million, and -$18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | -17.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.87 Mn |
| Mar 31, 2026 | -17.83 Mn |
| Dec 31, 2025 | -18.30 Mn |
| Sep 30, 2025 | -18.03 Mn |
| Jun 30, 2025 | -23.09 Mn |
| Mar 31, 2025 | -30.20 Mn |
| Dec 31, 2024 | -22.25 Mn |
| Sep 30, 2024 | -21.38 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Mar 31, 2024 | -18.02 Mn |
| Dec 31, 2023 | -19.40 Mn |
| Sep 30, 2023 | -23.36 Mn |
| Jun 30, 2023 | -19.52 Mn |
| Mar 31, 2023 | -16.32 Mn |
| Dec 31, 2022 | -14.94 Mn |
| Sep 30, 2022 | -18.61 Mn |
| Jun 30, 2022 | -17.32 Mn |
| Mar 31, 2022 | -18.25 Mn |
| Dec 31, 2021 | -7.14 Mn |
| Sep 30, 2021 | -8.11 Mn |